Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.
Saved in:
| Title: | Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma. |
|---|---|
| Authors: | Chen, Wenming1 (AUTHOR) 13910107759@163.com, Fu, Chengcheng2 (AUTHOR) fuchengchengsz@163.com, Fang, Baijun3 (AUTHOR), Liang, Aibin4 (AUTHOR), Xia, Zhongjun5 (AUTHOR), He, Yanjuan6 (AUTHOR), Lu, Jin7 (AUTHOR), Liu, Hui8 (AUTHOR), Hou, Ming9 (AUTHOR), Cai, Zhen10 (AUTHOR), Yang, Wei11 (AUTHOR), Hao, Siguo12 (AUTHOR), Jiang, Songfu13 (AUTHOR), Jing, Hongmei14 (AUTHOR), Liu, Jing15 (AUTHOR), Du, Xin16 (AUTHOR), Fu, Rong17 (AUTHOR), Mei, Heng18 (AUTHOR), Zhu, Zunmin19 (AUTHOR), Yang, Yanli20 (AUTHOR) |
| Source: | Experimental Hematology & Oncology. 9/30/2025, Vol. 14 Issue 1, p1-14. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
